Neurology

In instances when longer term treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of treatment and at least annually thereafter. If clinical effectiveness has not been achieved, IG should be discontinued.

Guillain-Barré Syndrome (GBS) including Miller-Fisher syndrome and other variants

Recommended Indications in which IG can be used

Order Number: N4-GBS

Lambert–Eaton Myasthenic Syndrome (LEMS)

Recommended Indications in which IG can be used

Order Number: N5-LEMS

Motor neuron disease

Do Not Use

Multifocal Motor Neuropathy (MMN)

Recommended Indications in which IG can be used

Order Number: N6-MMN

Multiple sclerosis (MS)

Do Not Use

Multiple Sclerosis (MS) – Relapsing remitting multiple sclerosis (RRMS), short-term therapy

Recommended Indications in which IG can be used

Order Number: N7-RRMS

Myasthenia Gravis (MG)

Recommended Indications in which IG can be used

Order Number: N8-MG

Myasthenia gravis (MG)- Mild / Ocular

Do Not Use

Myelin Oligodendrocyte Glycoprotein antibody-associated disorders (MOGAD) – pediatric

Recommended Indications in which IG can be used

Order Number: N9-MOGAD

Narcolepsy / cataplexy

Do Not Use